These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8903481

  • 1. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte T.
    Int J Cancer; 1996 Nov 04; 68(3):378-83. PubMed ID: 8903481
    [Abstract] [Full Text] [Related]

  • 2. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
    van Horssen PJ, van Oosterhout YV, Evers S, Backus HH, van Oijen MG, Bongaerts R, de Witte T, Preijers FW.
    Leukemia; 1999 Feb 04; 13(2):241-9. PubMed ID: 10025898
    [Abstract] [Full Text] [Related]

  • 3. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, Eling WM, De Witte T.
    Leuk Lymphoma; 2000 Nov 04; 39(5-6):591-9. PubMed ID: 11342342
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules.
    van Horssen PJ, van Oosterhout YV, de Witte T, Preijers FW.
    Scand J Immunol; 1995 Jun 01; 41(6):563-9. PubMed ID: 7770726
    [Abstract] [Full Text] [Related]

  • 7. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
    Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I.
    Int J Cancer; 1999 Mar 31; 81(1):148-55. PubMed ID: 10077166
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A, Tazzari PL, Olivieri F, Polito L, Lemoli R, Terenzi A, Pasqualucci L, Falini B, Stirpe F.
    Br J Haematol; 1998 Apr 31; 101(1):179-88. PubMed ID: 9576199
    [Abstract] [Full Text] [Related]

  • 12. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
    Mansfield E, Amlot P, Pastan I, FitzGerald DJ.
    Blood; 1997 Sep 01; 90(5):2020-6. PubMed ID: 9292538
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW.
    Int J Cancer; 1988 Nov 15; 42(5):792-7. PubMed ID: 3263328
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.
    Xenotransplantation; 2001 Aug 15; 8(3):157-71. PubMed ID: 11472623
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.